cardiovascular prevention

systematic review meta-analysis network meta-analysis

Select weight-loss drugscholesterol lowering interventionniacinPCSK9 Inhibitorsstatinsanticoagulantantiplatelets drugantithromboticsdirect factor Xa inhibitorsdirect oral anticoagulant (DAO)HDL increasing drugsACAT inhibitionantioxydantsCEPT inhibitiondietdietary salt reductionhormonal replacement therapylifestyle interventionomega-3 fatty acids on top statinsplasma homocysteine lowering interventionpolypill all chronical situationsAll type of patientDiabetic patientselderly patientshigh risk patients with or without LDL cholesterol elevationoverweight or obese patientspatients at low riskpatient with related diseasepatients at high riskPatients with LDL elevation and without CHDpatients with other atherosclerotic localisationpatients with prior MI or with CHDpatients undergoing dialysisuncoded clinical condition ***post stroke (or TIA)primary preventionsecondary prevention in patients with CADsecondary preventionsecondary prevention in patients with intermittent claudicationwomen       ACAT inhibitionanticoagulantantioxydantaspirinCETP inhibitorclopidogrelcolestipol-niacincombination therapiesdietdipyridamolendocannabinoid receptor ezetimibefibrateshormonal replacement therapyhormonesinhibitor of lipoprotein-associated phospholipaseMediterranean dietMultiple risk factor interventionsniacinniacin (on top statin)niacin in associationNOAComega-3 Fatty acidsother cholesterol lowering drugsP2Y12 receptor-antagonistPCSK9 Inhibitorplasma homocysteine lowering interventionplatelet aggregation inhibitorsPolicosanolpolypillProbucolresinsrimonabant selective PAR-1 thrombin receptor antagonistsodium reductionstatinsstatins high dosestatins+ezetimibestrategysurgeryticlopidineVKAVKA + antiplatelet atorvastatincerivastatinfluvastatinlovastatinpravastatinrosuvastatinsimvastatinezetimibebezafibratefenofibratepolicosanolvariouswafarinalirocumabanacetrapibaspirinbeta carotenebococizumabcholestyramineclofibrateclopidogrelcolestipoldicoumaroldietdipyridamolestrogenetofibrateevolocumab fish oilfolic acidgemfibrozilketanserineniacinomacorpactimibepicotamideprobucolrimonabantrivaroxabansulfinpyrazonesuloctidilthyroxineticagrelorticlopidinetorcetrapibvitamin cvitamin evorapaxarwarfarin vs controlvs placebovs placebo or controlvs active treatmentvs angioplastyvs aspirinvs ezetimibevs folic acid, vit B12 and vit B6vs statin       cerebral vascular diseaseearly initiationelderlyhypertensive patientskidney diseasesprimary preventionsecondary preventionsquamous NSCLCtype 2 diabetes

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (646)cardiovascular events (360)stroke (fatal and non fatal) (314)Non fatal MI (295)Coronary event (293)Coronary death (273)Cardiovascular death (254)non cardiovascular death (250)cardiac death (194)Rhabdomyolysis (79)Fatal stroke (78)Non fatal stroke (74)Death from cancer (73)Haemmorhagic stroke (71)Coronary death and non fatal MI (64)MACE (63)myocardial infarction (fatal and non fatal) (53)new-onset diabetes (48)ischemic stroke (46)Cancer (41)Fatal MI (38)Myopathy (34)Fatal bleeding (33)Venous thromboembolism (28)Vascular death (27)Adverse events (24)Major bleeding (24)Vascular events (23)Revascularization (23)Major gastrointestinal bleeding (18)Smoking prevalence (16)Non cerebral major bleeding (15)serious adverse events (15)death from all causes as adverse event (14)blood cholesterol concentration (12)puylmonary embolism (12)DBP change from baseline (mmHg) (11)intracranial hemorrhage (11)cardiovascular death, MI, stroke (11)cardiovascular events at 4 months (10)cardiovascular events at 1 month (10)SBP change from baseline (mmHG) (10)Gastrointestinal Bleeding (9)cardiovascular death as adverse event (8)Coronary revascularization (8)Non vascular death (8)Long term death (7)Amputation (7)Peptic ulcer (6)cardiovascular events including revascularization (6)Peripheral vascular events (5)stable angina (5)weight loss equal to or greater than 10 percent (5)long term cardiovascular events (5)Sudden death (4)cardiovascular events as adverse event (4)Neurocognitive disorder (4)fatal hemorrhagic stroke (4)non fatal hemorrhagic stroke (3)Hematuria (3)myocardial infarction as adverse event (3)Muscle-related adverse events (3)total cholesterol (at 1 y) (2)HDL (at 1 y) (2)LDL (2)End stage renal disease (2)unstable angina (2)TIA (2)weight loss equal to or greater than 5 percent (2)stroke or TIA (2)long term cardiovascular death (2)recurrent angina (2)CABG (2)PTCA (1)Deaths or MI (1)target lesion revascularisation (1)vision loss (1)retinopathy (1)Waist circumference change from baseline (cm) (1)Fasting glucose change (mmol/liter) (1)weight change from baseline (kg) (1)new-onset atrial fibrillation (1)neurological SAE (1)Allergic reactions (1)net benefit (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	cardiovascular events
ACAT inhibition
pactimibe
CAPTIVATE, 2009      NCT	pactimibe	placebo			Low risk of bias	-
ACTIVATE, 2006      NCT	pactimibe	placebo			Low risk of bias	-
anticoagulant
not classified
MacMillan, 1960	anticoagulant	no anticoagulant				-
Borchegrevink, 1960	anticoagulant	no anticoagulant				-
Clausen, 1961	anticoagulant	no anticoagulant				-
Harvald, 1961	anticoagulant	no anticoagulant				-
Conrad, 1964	anticoagulant	no anticoagulant				-
Wasserman, 1966	anticoagulant	no anticoagulant				-
Loeliger, 1967	anticoagulant	no anticoagulant				-
Lovell, 1967	anticoagulant	no anticoagulant				-
Seaman, 1969	anticoagulant	no anticoagulant				-
Sorensen, 1969	anticoagulant	no anticoagulant				-
Meuwisse,, 1969	anticoagulant	no anticoagulant				-
Drapkin and Merskey, 1972	anticoagulant	no anticoagulant				-
Sixty Plus Reinfarction, 1980	coumarin congeners	placebo			Low risk of bias	-
ASPECT, 1994	nicoumalone or phenprocoumon	placebo				-
Breddin, 1980	phenprocoumon	placebo			Low risk of bias	-
dicoumarol
Apenstrom and Korsan-Bengtsen, 1964	dicoumarol	no anticoagulant				-
rivaroxaban
COMPASS (rivaroxaban alone), 2017    NCT	rivaroxaban	aspirin	secondary prevention			-
COMPASS (rivaroxaban + aspirin), 2017      NCT	rivaroxaban + aspirin	aspirin	secondary prevention		Low risk of bias	-
wafarin
WARIS, 1990	warfarin	placebo			Low risk of bias	-
warfarin
Thrombosis Prevention trial (Warfarin), 1998        NCT	warfarin	placebo	primary prevention		Low risk of bias	suggesting
Thrombosis Prevention trial (W plus A), 1998        NCT	warfarin + aspirin	placebo	primary prevention		Low risk of bias	suggesting
antioxydants
not classified
Tepel, 2003	acetylcysteine	placebo			Low risk of bias	suggesting
HPS antioxidant, 2002	combination	placebo			Low risk of bias	negative
WAVE (Waters), 2002	combination	placebo			Low risk of bias	negative
POPADAD (antioxydant), 2008	combination	placebo			Low risk of bias	negative
PHS II beta carotene, 2003          NCT	combination	placebo			Low risk of bias	-
SUVIMAX, 2005	combination	placebo			Low risk of bias	negative
HATS, 2001	combination	placebo			Low risk of bias	negative
MVP, 1997	combination	placebo			Low risk of bias	negative
PHS II (multivitamin), 2012        NCT	combination	placebo			Low risk of bias	negative
ARISE, 2008      NCT	succinobucol	placebo			Low risk of bias	suggesting
beta carotene
ATBC beta carotene, 1994	beta carotene	placebo			Low risk of bias	-
CARET beta carotene, 1996	beta carotene	placebo			Low risk of bias	negative
SCP beta carotene, 1990	beta carotene	placebo			Low risk of bias	negative
NSCP (Green) beta carotene, 1999	beta carotene	placebo			Low risk of bias	negative
PHS beta carotene, 1996	beta carotene	placebo			Low risk of bias	suggesting
WHS beta carotene, 1999        NCT	beta carotene	placebo			Low risk of bias	negative
WACS beta-caroten, 2007        NCT	beta carotene	placebo			Low risk of bias	negative
ATBC 2nd prev subgroup (b carotene), 1998	beta carotene	placebo			Low risk of bias	negative
vitamin c
WACS vitamin C, 2007        NCT	vitamin C	placebo			Low risk of bias	negative
PHS II vitamin C, 2008    NCT	vitamin C	placebo			Low risk of bias	negative
vitamin e
GISSI, 1999	vitamin E	control			Risk of bias	negative
PPP, 2001	vitamin E	control			Risk of bias	negative
ATBC vitamin E, 1994	vitamin E	placebo			Low risk of bias	suggesting
CHAOS, 1996	vitamin E	placebo			Low risk of bias	suggesting
HOPE, 2000	vitamin E	placebo			Low risk of bias	negative
AREDS, 2001	vitamin E	placebo			Low risk of bias	negative
Linxian, 1993	vitamin E	placebo				negative
WACS vitamin E, 2007        NCT	vitamin E	placebo			Low risk of bias	negative
PHS II vitamin E, 2008    NCT	vitamin E	placebo			Low risk of bias	negative
WHS vitamin E, 2005      NCT	vitamin E	placebo			Low risk of bias	negative
ASAP, 2000	vitamin E	placebo			Low risk of bias	negative
SPACE, 2000	vitamin E	placebo			Low risk of bias	suggesting
HOPE renal insufficiency subgroup, 2004	vitamin E	placebo			Low risk of bias	negative
ATBC 2nd prev subgroup (vitamin E), 1998	vitamin E	placebo			Low risk of bias	negative
antiplatelets drug
aspirin
JPAD, 2008      NCT	aspirin	no treatment			Risk of bias	suggesting
PPP (diabetics sub group), 2003	aspirin	no treatment			Exploratory	negative
British Doctor’s Trial, 1988	aspirin	no treatment	primary prevention		Risk of bias	negative
Primary Prevention Project, 2001	aspirin	no treatment	primary prevention		Risk of bias	negative
POPADAD aspirin, 2008	aspirin	placebo			Low risk of bias	negative
DAMAD, 1989	aspirin	placebo			Low risk of bias	negative
ETDRS, 1992	aspirin	placebo			Low risk of bias	suggesting
PHS (diabetics sub group), 1989	aspirin	placebo			Low risk of bias	suggesting
WHS (diabetics sub group), 2005	aspirin	placebo			Low risk of bias	suggesting
Physicians Health Study, 1989    NCT	aspirin	placebo	primary prevention		Low risk of bias	suggesting
Thrombosis Prevention Trial, 1998        NCT	aspirin	placebo	primary prevention		Low risk of bias	suggesting
HOT, 1998	aspirin	placebo	primary prevention		Low risk of bias	suggesting
Women’s Health Study, 2005	aspirin	placebo	primary prevention		Low risk of bias	suggesting
AAA, 2009	aspirin	placebo	secondary prevention		Low risk of bias	negative
ASPREE, 2018    NCT	aspirin	placebo				-
ASCEND, 2018      NCT	aspirin	placebo				suggesting
Schoop, 1983	aspirin	placebo			Low risk of bias	-
Hess, 1985	aspirin	placebo				-
Munich A, 1975	aspirin	placebo			Low risk of bias	-
Munich B, 1975	aspirin	placebo			Low risk of bias	-
CLIPS, 2007	aspirin	placebo			Low risk of bias	suggesting
CDPA, 1976	aspirin	placebo			Low risk of bias	negative
Cardiff I, 1974	aspirin	placebo			Low risk of bias	negative
Cardiff II, 1979	aspirin	placebo			Low risk of bias	negative
Vogel, 1979	aspirin	placebo			Low risk of bias	suggesting
AMIS, 1980    NCT	aspirin	placebo			Low risk of bias	suggesting
GAMIS, 1980	aspirin	placebo			Low risk of bias	negative
PARIS, 1980	aspirin	placebo			Low risk of bias	negative
JAMIS, 1999	aspirin	placebo				suggesting
SAPAT, 1992	aspirin	placebo			Low risk of bias	suggesting
clopidogrel
CAPRIE, 1996	clopidogrel	aspirin	secondary prevention		Low risk of bias	suggesting
CAPRIE (PAD subgroup), 1996	clopidogrel	aspirin			Low risk of bias	suggesting
ASCET    NCT	clopidogrel	aspirin			Risk of bias	negative
CHARISMA, 2006      NCT	clopidogrel	placebo (on top aspirin)	secondary prevention		Low risk of bias	suggesting
dipyridamol
Atlanta (Sbar), 1967	dipyridamol	control			Low risk of bias	negative
Becker, 1967	dipyridamol	control			Low risk of bias	negative
Wirecki, 1967	dipyridamol	control			Low risk of bias	negative
Hess (2), 1985	aspirin + dipyridamol	placebo			Low risk of bias	-
Schoop (2), 1983	aspirin + dipyridamol	placebo			Low risk of bias	-
VA study, 1986	aspirin + dipyridamol	placebo			Low risk of bias	-
Igloe, 1970	dipyridamol	placebo			Low risk of bias	-
Zion, 1961	dipyridamol	placebo			Low risk of bias	-
Kinsella, 1962	dipyridamol	placebo			Low risk of bias	-
Leiberman, 1964	dipyridamol	placebo			Low risk of bias	-
Dewar, 1961	dipyridamol	placebo			Low risk of bias	-
Neumann, 1964	dipyridamol	placebo			Low risk of bias	-
Foulds, 1960	dipyridamol	placebo			Low risk of bias	-
PARIS, 1980	dipyridamol + aspirin	placebo			Low risk of bias	negative
PARIS-II, 1986	dipyridamol + aspirin	placebo			Low risk of bias	negative
PARIS, 1980	dipyridamol + aspirin	aspirin			Low risk of bias	negative
ketanserine
PACK, 1996	ketanserine	placebo			Low risk of bias	-
Walden, 1991	ketanserine	placebo			Low risk of bias	-
Thulesius, 1987	ketanserine	placebo			Low risk of bias	-
picotamide
Cocozza, 1995	picotamide	placebo			Low risk of bias	negative
ADEP, 1993	picotamide	placebo			Low risk of bias	-
Neirotti, 1994	picotamide	placebo			Low risk of bias	-
Coto, 1989	picotamide	placebo			Low risk of bias	-
sulfinpyrazone
Dutch, 1980	sulfinyrazone	placebo				negative
suloctidil
Adriaensen, 1976	suloctidil	placebo			Low risk of bias	-
Verhaeghe, 1981	suloctidil	placebo			Low risk of bias	-
Jones, 1982	suloctidil	placebo			Low risk of bias	-
Holm, 1984	suloctidil	placebo			Low risk of bias	-
ticagrelor
EUCLID, 2016        NCT	ticagrelor	clopidogrel			Low risk of bias	-
PEGASUS 60mg, 2015        NCT	ticagrelor	placebo (on top aspirin)	secondary prevention		Low risk of bias	suggesting
PEGASUS 90mg, 2015        NCT	ticagrelor	placebo (on top aspirin)	secondary prevention		Low risk of bias	suggesting
ticlopidine
Birmingham-A, 1979	ticlopidine	placebo				negative
London diabetes, 1983	ticlopidine	placebo				negative
TIMAD, 1984	ticlopidine	placebo				negative
BTRS, 1992	ticlopidine	placebo			Low risk of bias	negative
Nyberg, 1984	ticlopidine	placebo			Low risk of bias	negative
EMATAP, 1993	ticlopidine	placebo			Low risk of bias	-
Katsumara, 1982	ticlopidine	placebo			Low risk of bias	-
Aukland, 1982	ticlopidine	placebo			Low risk of bias	-
Stiegler, 1984	ticlopidine	placebo			Low risk of bias	-
Ellis, 1986	ticlopidine	placebo			Low risk of bias	-
Cloarec, 1986	ticlopidine	placebo			Low risk of bias	-
Arcan, 1988	ticlopidine	placebo			Low risk of bias	-
Balsano, 1989	ticlopidine	placebo			Low risk of bias	-
STIMS, 1990	ticlopidine	placebo			Low risk of bias	-
Hurlow, 1980	ticlopidine	placebo			Low risk of bias	-
Krause, 1980	ticlopidine	placebo			Low risk of bias	-
Berglund, 1985	ticlopidine	placebo			Low risk of bias	negative
various
CRAMPS, 2000	cloricromene	placebo			Low risk of bias	-
vorapaxar
TRA-2P TIMI 50, 2012        NCT	vorapaxar	placebo (on top aspirin)	secondary prevention		Low risk of bias	suggesting